我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
2
0 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
N/A
已完成
1
50.0%
招募中
暂无批准数据
- The largest study to date testing leucovorin for autism traits has been retracted by the European Journal of Pediatrics due to data inconsistencies and statistical errors that could not be replicated. - The retraction removes significant evidence supporting leucovorin use in autism, leaving researchers with limited and inconsistent data as the FDA considers expanding the drug's approval for cerebral folate deficiency. - A new 80-child trial led by Richard Frye is expected to provide clearer evidence by early 2026, representing the most robust test of leucovorin's effectiveness in autistic children to date.
